Yi‐Peng Fu
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 10%
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Hepatocellular Carcinoma Treatment and Prognosis 7
-
- Cancer, Lipids, and Metabolism 5
- MicroRNA in disease regulation 3
- Co-authors
- Yong Yi (17 shared papers)Jian Zhou (15 shared papers)Shuang–Jian Qiu (15 shared papers)Jia Fan (14 shared papers)Xiaochun Ni (10 shared papers)Jinlong Huang (9 shared papers)Wei Gan (9 shared papers)Chuyu Jing (9 shared papers)
In The Last Decade
Yi‐Peng Fu
31 papers receiving 845 citations
Peers
Comparison fields: 5 of 74
- Hepatology 132
- Oncology 302
- Cancer Research 142
- Physiology 42
- Immunology 148
Countries citing papers authored by Yi‐Peng Fu
This map shows the geographic impact of Yi‐Peng Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi‐Peng Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi‐Peng Fu more than expected).
Fields of papers citing papers by Yi‐Peng Fu
This network shows the impact of papers produced by Yi‐Peng Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi‐Peng Fu. The network helps show where Yi‐Peng Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Yi‐Peng Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 95 | |
| 2 | 2020 | 87 | |
| 3 | 2016 | 64 | |
| 4 | 2016 | 62 | |
| 5 | 2020 | 55 | |
| 6 | 2015 | 50 | |
| 7 | 2018 | 38 | |
| 8 | 2016 | 35 | |
| 9 | 2017 | 34 | |
| 10 | 2016 | 32 | |
| 11 | 2019 | 28 | |
| 12 | 2021 | 28 | |
| 13 | 2017 | 23 | |
| 14 | 2018 | 20 | |
| 15 | 2021 | 20 | |
| 16 | 2015 | 19 | |
| 17 | 2016 | 19 | |
| 18 | 2020 | 17 | |
| 19 | 2017 | 16 | |
| 20 | 2016 | 16 |
About Yi‐Peng Fu
Yi‐Peng Fu is a scholar working on Hepatology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 31 papers that have together received 852 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Inflammatory Biomarkers in Disease Prognosis (6 papers), Cancer, Lipids, and Metabolism (5 papers), Ferroptosis and cancer prognosis (3 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), MicroRNA in disease regulation (3 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Hepatology (132 citations), Oncology (302 citations), Cancer Research (142 citations), Physiology (42 citations) and Immunology (148 citations). Yi‐Peng Fu has collaborated with scholars based in China, Ethiopia and Germany. Frequent co-authors include Yong Yi, Jian Zhou, Shuang–Jian Qiu, Jia Fan, Xiaochun Ni, Jinlong Huang, Wei Gan, Chuyu Jing, Jiaxing Wang and Xiaoyan Cai. Their work appears in journals such as Medicine, Journal of Surgical Oncology, Oncotarget, Journal for ImmunoTherapy of Cancer and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.